Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial
一项多中心、随机、双盲、安慰剂对照的3期临床试验，旨在评估cAMP信号通路偏向性GLP-1类似物依诺鲁肽单药治疗与安慰剂治疗2型糖尿病患者的疗效和安全性（EECOH-1）：
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-68165-7
Zhu, Dalong; Wang, Weimin; Tong, Guoyu; Ma, Jianhua; Wen, Binhong; Zheng, Xin; Shi, Bimin; Pang, Shuguang; Wang, Kun; Shi, Xiaoxia; Zhang, Xianghua; Fu, Liujun; Liu, Yang; Lu, Yibing; Huang, Debin; Jiang, Chengxia; Pan, Tianrong; Xue, Haibo; Han, Jie; Ding, Hongcheng; Bing, Shaohui; Jiang, Feifei; Zheng, Qing; Yang, Ming; Guan, Lei; Liu, Xingquan; Ning, Jing; Bu, Yue; Guo, Mengying; Yang, Liu; Guo, Wanjun; Li, Yao; Xu, Susan; Pan, Hai
GLP-1
信号转导
代谢
GPCR/Calcium/cAMP
糖尿病
